Progyny (PGNY) Jefferies London Healthcare Conference 2024 summary
Event summary combining transcript, slides, and related documents.
Jefferies London Healthcare Conference 2024 summary
13 Jan, 2026Utilization and financial trends
Utilization rates remained high, but cycles per utilizer declined compared to historical patterns, with a drop in Q3 and early signs of reversal in Q4.
Inflation and macroeconomic uncertainty may have influenced individual decisions, but overall utilization stayed strong.
Membership is forecasted to reach 6.7 million in January, with no significant leakage; some new members started early.
Client retention remains at 99%, with only five clients leaving out of over 460, and many clients expanding benefits.
Analysts' revenue and EBITDA forecasts for 2025 appear conservative, likely due to assumptions of continued lower cycles per utilizer, despite improving trends in Q4.
Sales season and competitive landscape
1.1 million lives were added in the latest selling season, with strong wins among large clients and a robust active pipeline remaining.
No significant pushback from employers on benefit coverage; competing priorities include medical cost inflation and health plan changes.
Industry penetration is not yet saturated; about 50% of large employers offer some fertility coverage, but true comprehensive coverage is much lower.
Competition from standalone providers and carriers remains, but win rates against competitors are strong, with more than double the wins versus losses.
Partnerships with managed care organizations are increasing, shifting some former competitors into collaborators.
Product expansion and upsell activity
New maternity and menopause solutions are being adopted, with 1.5 million covered lives expected for these products in 2025.
These solutions are case-rate based and expected to become meaningful revenue contributors over time as awareness and utilization grow.
30% of clients bought additional services during the selling season, with no trend of clients reducing coverage.
Upsell activity correlates with increased utilization and revenue over time, and the average client now has more cycles than at IPO.
Latest events from Progyny
- Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026 - Utilization rebounded after a Q1 dip, with strong membership growth and a favorable outlook.PGNY
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Q3 revenue up 2%, net income and margins down; new clients, services, and buybacks offset client loss risk.PGNY
Q3 202414 Jan 2026 - Progyny Select expands reach to small employers, fueling growth and diversification in 2026.PGNY
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Growth, retention, and new women's health offerings drive market leadership and value.PGNY
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026